Cambiar Aggressive Value ETF (CAMX)
| Assets | $64.36M |
| Expense Ratio | 0.59% |
| PE Ratio | 18.51 |
| Shares Out | 1.94M |
| Dividend (ttm) | $0.57 |
| Dividend Yield | 1.72% |
| Ex-Dividend Date | Dec 30, 2025 |
| Payout Frequency | Semi-Annual |
| Payout Ratio | 31.78% |
| Volume | 144 |
| Open | 33.25 |
| Previous Close | 33.36 |
| Day's Range | 33.25 - 33.25 |
| 52-Week Low | 26.45 |
| 52-Week High | 33.50 |
| Beta | 0.76 |
| Holdings | 30 |
| Inception Date | Feb 13, 2023 |
About CAMX
Fund Home PageThe Cambiar Aggressive Value ETF (CAMX) is an exchange-traded fund that mostly invests in total market equity. The fund is an actively managed, global equity fund. Stock selection and weighting is based on the Issuers strongest belief for long-term capital appreciation. CAMX was launched on Feb 13, 2023 and is issued by Cambiar Funds.
Top 10 Holdings
44.88% of assets| Name | Symbol | Weight |
|---|---|---|
| Elevance Health, Inc. | ELV | 5.50% |
| Uber Technologies, Inc. | UBER | 5.04% |
| Honeywell International Inc. | HON | 4.81% |
| Union Pacific Corporation | UNP | 4.75% |
| Texas Instruments Incorporated | TXN | 4.56% |
| Medtronic plc | MDT | 4.12% |
| NXP Semiconductors N.V. | NXPI | 4.09% |
| Masco Corporation | MAS | 4.02% |
| Nintendo Co., Ltd. | NTDOY | 4.00% |
| CME Group Inc. | CME | 3.98% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 30, 2025 | $0.4793 | Jan 7, 2026 |
| Sep 25, 2025 | $0.0914 | Sep 26, 2025 |
| Dec 30, 2024 | $0.3884 | Jan 7, 2025 |
| Dec 28, 2023 | $0.1464 | Jan 5, 2024 |
Performance
CAMX had a total return of 9.63% in the past year, including dividends. Since the fund's inception, the average annual return has been 12.79%.
News
Camurus announces FDA acceptance of NDA resubmission for Oclaiz™ for the treatment of acromegaly
PDUFA target action date set to 10 June 2026 LUND, Sweden, Jan. 9, 2026 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for rev...
Camurus announces positive Phase 3 results from the ACROINNOVA 2 study of octreotide SC depot (CAM2029) in acromegaly patients
Treatment well tolerated with a safety profile consistent with standard-of-care (SoC) Increased biochemical response rates (IGF-1 ≤ 1xULN) vs SoC at baseline Continuous improvement of acromegaly sympt...
Cambiar Investors Launches Aggressive Value ETF
DENVER--(BUSINESS WIRE)--Cambiar Investors announces the launch of a new active ETF.